Shekher Mohan PhD

Associate Professor of Pharmacology

(434) 582-2824


  • B.Sc. (Hons) Pharmacology: University of Hertfordshire, England, UK
  • PhD, Biomedical Science: Pharmacology, Oklahoma State University, College of Medicine
  • Postdoc., Anesthesiology & Pain, University of Iowa, College of Medicine
  • Postdoc., Critical Care & Stroke, University of Florida, College of Medicine

Courses Taught

  • Biomedical Foundations of Osteopathic Medicine (BFOM)
  • Cardiovascular and Pulmonology (CP)
  • Cardiovascular, Respiratory, Hematological Systems (CVRH)
  • Endocrinology (ENDO)
  • Endocrinology and Reproduction (ENDOREP)
  • Gastroenterology (GI)
  • Gastrointestinal System and Nutrition (GINUTRI)
  • Geriatrics (GERI)
  • Hematology and Oncology (HO)
  • Integument and Musculoskeletal Systems (IMSK)
  • Neurology, Psychiatry and Ophthalmology (NPO)
  • Orthopedics, Rheumatology, Dermatology (ORD)
  • Urinary and Renal Systems (URI)

Professional Memberships

  • American Association of Colleges of Pharmacy (AACP)
  • American Society for Pharmacology and Experimental Therapeutics (ASPET)
  • Psychoneuroimmunology Research Society (PNIRS)
  • Society For Behavioral Neuroendocrinology (SBN)
  • Society for Neuroscience (SfN)


Dr. Shekher Mohan is an Associate Professor of pharmacology. As a native of England, UK he received his bachelor’s degree in pharmacology from Univ., of Hertfordshire, and then attended Oklahoma State Univ., College of Medicine, receiving his PhD in pharmacology. He completed two postdoctoral fellowships: first at the Univ. of Iowa, College of Medicine, in the Dept. of Anesthesia (2009-2010) and the second at Univ. of Florida, College of Medicine, in the Dept. of Anesthesiology as a NIH F32-NRSA Fellow (2010-2014). During his time at Univ. of Florida, his research focused on inflammation and neuroprotection pertaining to hemorrhagic stroke using novel preclinical models. He also served as Chapter President for the North Central Florida Chapter of the Society for Neuroscience (SfN)

Prior to arriving at LUCOM, Dr. Mohan was an assistant professor of pharmacology at Marshall Univ., School of Pharmacy (2014 to 2017), and at Manchester Univ., College of Pharmacy (2017 to 2020), where he has obtained research grants to support a project to improve the understanding of the role of glia and neurons in opioid addiction and withdrawal using a novel preclinical model.

Dr. Mohan is currently an Advisory Board Member for the Sia Brain Awareness Foundation and serves as a peer-journal reviewer for numerous journals such as Frontiers in Neuropharmacology and BMC Neuroscience and is on the editorial boards of numerous journals such as the J. Pharmaceutical Sciences and Annuals in Pharmacology & Pharmaceutics. He also currently serves as the Associate Editor for Heliyon® (Cell Press) in the section of Pharmacology and Toxicology.


  • Stevens. S., Mohan. S. Opioid Withdrawal Behavior in Spiny Mice: A Novel Preclinical Model of Neonatal Opioid Withdrawal Syndrome (NOWS). Heliyon-Neuroscience (Cell Press®) March 2021
  • Stevens. S., (Ph.D. candidate), Siefert. A.W., Mohan. S. Gender Differences of Withdrawal Behavior in Spiny Mice: A Novel Preclinical Model of Neonatal Opioid Withdrawal Syndrome (NOWS). Behavioral Pharmacology (In progress). 2020
  • E. F. Kheir Pharm.D., RPh (Class of 2019) and S. Mohan. Management and Treatment of Parkinson Disease: A Pharmacist’s Guide. August 22nd 2019
  • Stevens. S., (Ph.D. student) Flaugher. T., Hughes. K., Terrwilliger. C., Hicks. M., (P3 pharmacy students), Mohan. S. Gender Difference in Withdrawing Infants. Global Pediatric Health., March 2018 (DOI: 10.1177/2333794X18775886)
  • Mohan. S., Koller. J.E., Fazal A. F., De Oliveira G.A., Pawlowicz. I. A., (undergraduates), Dore. S. Genetic deletion of F2α-FP receptor exacerbates brain injury after experimental intracerebral hemorrhage. Frontiers Neuroscience. September 2018 (DOI: 10.3389/fnins.2018.00556)
  • Stevens. S., (Ph.D. student) Heffner. C., Flaugher. T., (P3 pharmacy students), Mohan. S. Neonatal Abstinence Syndrome (NAS): Neurodevelopmental Challenges, Current Management and Future Directions. Current Opinions in Neurological Science. M2017 (
  • Mohan. S., Interleukin-1beta: a common thread between inflammation, pain and opioid tolerance. Neuroimmunology and Neuroinflammation, September 2016 (10.20517/2347-8659.2016.37)
  • Mohan. S., Robinson TJ., Armstrong L., (undergraduates), Allen N. (P3 pharmacy student), Stevens. S., (Ph.D. student). Morphine-mediated cytoprotection from hemin in SK-N-SH and A172 cells. Neurochemistry & Neuropharmacology. September 2016
  • Mohan. S., Dore. S. Neuroprotective Role of Prostaglandin-EP2 receptor in hemin-mediated toxicity. NeuroToxicology. November, 2015, (DOI: 10.1016/j.neuro.2014.10.012)
  • Ameli P.A., Ameli N.J., Gubernick D.M., Ansari S., Mohan S., Buckley A. K., Maxwell C.W., Nayak V.H., Hedna V.S. The role of vasopressin and its antagonism in stroke related edema. J. Neurosci Res. 92(9): 1091-9, 2014 (DOI: 10.1002/jnr.23407)
  • Mohan. S., Glushakov. A.V., deCurnou A. (undergraduate), Dore. S. Contribution of PGE2 EP1 receptor in hemin-induced neurotoxicity. Frontiers in Mol. Neurosci. 6(31), 2013 (DOI: 10.3389/fnmol.2013.00031)
  • Mohan. S., Ahmad, A.S., Glushakov A.V., Chamber. C. (undergraduate), Dore. S. Putative role of prostaglandin receptor in intracerebral hemorrhage. Frontiers in Neurology 3(145), 2012 (DOI: 10.3389/fneur.2012.00145)
  • Mohan. S., Spofford C.M., Kang. S, Jang J.H. and Brennan T.J. Evaluation of Leukemia Inhibitory Factor in a rodent model of postoperative pain. (Front cover) J. Pain 12(7): 819-32, 2011 (DOI: 10.1016/j.jpain.2011.02.351)
  • Mohan. S., Davis R.L., DeSilva U. and Stevens C.W. Dual regulation of mu-opioid receptors in SK-N-SH neuroblastoma cells by morphine and interleukin-1beta: evidence for opioid-immune crosstalk. J. Neuroimmunology 227(1-2): 26-34, 2010 (DOI 10.1016/j.jneuroim.2010.06.007.)
  • Davis R.L., Buck D.J., Saffarian N, Mohan. S., DeSilva U and Stevens C.W. β-Funaltrexamine inhibits inducible nitric-oxide synthase expression in human astroglial cells.  J. NeuroImmune., Pharmacology. 3(3): 150-153, 2008 (DOI: 10.1007/s11481-008-9102-x)
  • Stevens C.W., Brasel C.M., and Mohan. S. Cloning and bioinformatics of amphibian mu, delta, kappa and nociceptin opioid receptors expressed in brain tissue: Evidence for opioid receptor divergence in mammals. Neuroscience Letters 419: 189-194, 2007 (DOI: 10.1016/j.neulet.2007.04.014.)
  • Mohan. S., and Stevens C.W. Systemic and Spinal Administration of mu-opioid, Remifentanil produces antinociception in Amphibians. Eur. J. Pharmacology 18; 534(1-3): 89-94, 2006 (DOI: 10.1016/j.ejphar.2006.01.011.)

Research Interests

  • Role of glia and neuronal in the development of addiction and withdrawal
  • Pharmacogenomics – addiction
  • Neonatal Abstinence Syndrome (NAS)
  • Neurotoxicity – neurodevelopment and neurobehavior